MedTrace Logo

Tofacitinib Versus Methotrexate as the First Line DMARD in the Treatment of Rheumatoid Arthritis

NCT04464642 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 110

Last updated 2020-07-09

No results posted yet for this study

Summary

It is a randomized controlled study

Conditions

Interventions

DRUG

Methotrexate

Methotrexate 25 mg subcutaneous is given in group A

DRUG

Tofacitinib

tofacitinib 10 mg given in group B

Sponsors & Collaborators

  • Dr. Mohammad Mamun Khan

    lead OTHER

Principal Investigators

  • Mohammad M Khan, MBBS · Resident doctor, BSMMU

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-10
Primary Completion
2020-08-31
Completion
2020-09-30

Countries

  • Bangladesh

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04464642 on ClinicalTrials.gov